A novel drug-eluting coronary artery implant that “uncages” after 6 months appears to have similar short-term performance to a drug-eluting stent while maintaining flexibility of the treated artery, according to an early study in humans. A single-arm study of 20 patients who received the novel implant (DynamX drug-eluting bioadaptor, Elixir Medical) was published in Cardiovascular